View source for Encainide

==Administration==
*Type: Class IC antiarrhythmic (sodium channel blocker)
*Dosage Forms: Capsules (25mg or 35mg)
*Routes of Administration: PO
*Common Trade Names: Enkaid

==Adult Dosing==
===Sustained [[ventricular tachycardia]]===
* 25mg PO t.i.d
**May be increased to 35mg PO t.i.d after 3-5 days

==Pediatric Dosing==
*Safety and effectiveness in pediatrics not established

==Special Populations==
===[[Drug pregnancy categories|Pregnancy Rating]]===
*Category B

===Lactation risk===
*Unknown risk to nursing infants

===Renal Dosing===
*Adult: Reduce to single initial daily 25mg dose; increase to 25mg b.i.d after 7 days if needed.
*Pediatric: N/A

===Hepatic Dosing===
*Adult: No adjustments needed, but use caution when increasing dosage
*Pediatric: N/A

==Contraindications==
*Allergy to class/drug
*Preexisting 2nd or 3rd-degree AV block
*Preexisting right bundle branch block w/ left hemiblock
*Presence of cardiogenic shock

==Adverse Reactions==
===Serious===
*Provocation or aggravation of ventricular arrhythmias
*2nd or 3rd-degree AV block
*Sinus bradycardia

===Common===
* Dizziness
* Blurred/abnormal vision
* Headache

==Pharmacology== 
*Half-life: Genetically determined; 1-2 hours for 90% of patients; 6-11 hours for 10% of patients<ref>Gruetter, C., 2016. Encainide - an overview | ScienceDirect Topics. [online] Sciencedirect.com. Available at: <https://www.sciencedirect.com/topics/medicine-and-dentistry/encainide> [Accessed 27 June 2021].</ref>
*Metabolism: Hepatic; Encainide converts to two active metabolites (ODE and MODE)
*Excretion: Urine and feces
*Mechanism of action: Blocks sodium channels in purkinje fibers and myocardium; slows conduction, reduces membrane responsiveness, and inhibits automaticity<ref>Drugs.com. 2021. Enkaid - FDA prescribing information, side effects and uses. [online] Available at: <https://www.drugs.com/pro/enkaid.html#s-34067-9> [Accessed 27 June 2021].</ref>

==Comments==


==See Also==


==References==
<references/>

[[Category:Pharmacology]]